CANF – can-fite biopharma ltd sponsored adr (israel) (US:NASDAQ)

News

Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia [Yahoo! Finance]
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com